Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 510K | 350K | 0 | 0 | 0 |
| Gross Profit | 155K | 153K | 0 | 0 | 0 |
| Operating Income | -1M | -10K | -2M | -2M | -344K |
| EBITDA | -1M | 22K | 4M | 9M | -3M |
| Net Income | -1M | 14K | 4M | 9M | -3M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$2.42
-3.97% today
Window Change
-42.17%
Window
Aug 28, 2025 → Jun 1, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 190 bars · Aug 28, 2025 → Jun 1, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
YD Bio Limited Ordinary Shares (YDES) is a Healthcare stock with a market cap of $350.00M and listed on NASDAQ. The stock last traded around $2.42 and down 42.2% across the available one-year price window (Aug 28, 2025 → Jun 1, 2026). Baseline metrics include revenue growth of +45.8%, EPS growth of -280100.0%, a dividend yield of 0.0%. What stands out right now is revenue +45.8%, EPS -280100.0%, free cash flow -8386.3% with operating margin 0.0% and ROIC 13.6%. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines YDES price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
YDES
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
YDES Max Drawdown
-86.74%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for YDES and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$2.5M
-129.2% YoY
Free Cash Flow
-$253.6K
+63.2% YoY
Revenue Growth
+45.8%
EPS Growth
-280100.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 510K | 350K | 0 | 0 | 0 |
| Gross Profit | 155K | 153K | 0 | 0 | 0 |
| Operating Income | -1M | -10K | -2M | -2M | -344K |
| EBITDA | -1M | 22K | 4M | 9M | -3M |
| Net Income | -1M | 14K | 4M | 9M | -3M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3M | 87K | 14K | 5K | 694K |
| Total Assets | 7M | 321K | 18M | 118M | 118M |
| Total Liabilities | 274K | 298K | 7M | 9M | 18M |
| Shareholder Equity | 7M | 23K | 11M | 109M | 100M |
| Total Debt | 23K | 48K | 0 | 0 | 0 |
| Net Debt | -3M | -40K | -14K | -5K | -694K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
254K
+63.2% YoY
Capital Expenditures
5
+200.0% YoY
Free Cash Flow
254K
+63.2% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
68.2%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.